Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
Journal of Medicinal Chemistry
|
December 6, 2019
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
European Journal of Medicinal Chemistry
|
December 30, 2016
A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR<sup>L858R/T790M</sup> mutant with improved pharmacokinetic properties
Lei Yu, Minhao Huang, Tianfeng Xu, et al.
Journal of Medicinal Chemistry
|
March 1, 2022
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
Chuan Zhou, Zisheng Fan, Zehui Zhou, et al.
ACS Medicinal Chemistry Letters
|
August 14, 2024
Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors
Hualin Zhang, Yutong Tu, Zhaofan Tao, et al.
Journal of Medicinal Chemistry
|
April 28, 2020
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong <i>In Vivo</i> Antitumor Activity
Shilin Xu, Angelo Aguilar, Liyue Huang, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2023
Design, Synthesis, and Bioevaluation of Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Potent SOS1 Inhibitors
Meiying Liu, Guizhen Zhou, Wenhong Su, et al.
Nature Communications
|
July 26, 2022
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
Jing Gao, Bo Hou, Qiwen Zhu, et al.
Journal of Medicinal Chemistry
|
January 11, 2019
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Xin Han, Chao Wang, Chong Qin, et al.
Leukemia
|
March 26, 2026
Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity
Yutong Tu, Xiaojia Cai, Zhaofan Tao, et al.
Journal of Medicinal Chemistry
|
August 12, 2024
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Changwei Wang, Mi Wang, Yu Wang, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
Journal of Medicinal Chemistry
|
December 6, 2019
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
European Journal of Medicinal Chemistry
|
December 30, 2016
A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFR<sup>L858R/T790M</sup> mutant with improved pharmacokinetic properties
Lei Yu, Minhao Huang, Tianfeng Xu, et al.
Journal of Medicinal Chemistry
|
March 1, 2022
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
Chuan Zhou, Zisheng Fan, Zehui Zhou, et al.
ACS Medicinal Chemistry Letters
|
August 14, 2024
Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors
Hualin Zhang, Yutong Tu, Zhaofan Tao, et al.
Journal of Medicinal Chemistry
|
April 28, 2020
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong <i>In Vivo</i> Antitumor Activity
Shilin Xu, Angelo Aguilar, Liyue Huang, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2023
Design, Synthesis, and Bioevaluation of Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Potent SOS1 Inhibitors
Meiying Liu, Guizhen Zhou, Wenhong Su, et al.
Nature Communications
|
July 26, 2022
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
Jing Gao, Bo Hou, Qiwen Zhu, et al.
Journal of Medicinal Chemistry
|
January 11, 2019
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Xin Han, Chao Wang, Chong Qin, et al.
Leukemia
|
March 26, 2026
Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity
Yutong Tu, Xiaojia Cai, Zhaofan Tao, et al.
Journal of Medicinal Chemistry
|
August 12, 2024
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9
Changwei Wang, Mi Wang, Yu Wang, et al.
Page
of 6